Lupin’s UK subsidiary -- Lupin Healthcare (UK) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva. Lutio has the potential to offer significant cost savings when available to UK patients.
Tiotropium is used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD), a group of diseases that affect the lungs and airways) such as chronic bronchitis and emphysema. This is the second inhalation product by Lupin Healthcare for the UK market after Luforbec pressurised metered dose inhaler (pMDI).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
